Safety Study of Tecadenoson to Treat Atrial Fibrillation

Inclusion Criteria

• •Have a diagnosis of atrial fibrillation in need of treatment for rate control
• •Be able and willing to abstain from any antiarrhythmics, including atrioventricular (AV) nodal blocking agents (except for esmolol per protocol), from no later than 8:00 p.m. on the day prior to dosing until completion of the last dose period assessment
• •Be able and willing to abstain from xanthine- or chocolate-containing foods, beverages, and medications
• •Females must be post-menopausal or sterilized; or if of childbearing potential, must not be breastfeeding and must have a negative pregnancy test at screening and no intention of becoming pregnant during the course of the study. Males and females must be using adequate contraception during the study.